Rapid Dose Escalation of Quetiapine versus Conventional Escalation in Acute Schizophrenic Patients

Study identifier:D1441L00032

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Rapid Dose Escalation of Quetiapine versus Conventional Escalation in the Treatment of Patients with Acute Schizophrenia – a Multicentre, Double-blind, Parallel group, Randomized Study

Medical condition

schizophrenia

Phase

Phase 2

Healthy volunteers

Study drug

IR (Immediate-Release) quetiapine fumarate (drug)

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 Jun 2005

Primary Completion Date: -

Study Completion Date: 01 Jan 2006

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Jun 2009 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca GmbH

+49 4103 708 0

Investigators

Principal Investigator

AstraZeneca Germany Medical Director